[go: up one dir, main page]

PE20080404A1 - Derivados bencil-amino-piperidina como inhibidores de cetp - Google Patents

Derivados bencil-amino-piperidina como inhibidores de cetp

Info

Publication number
PE20080404A1
PE20080404A1 PE2007000936A PE2007000936A PE20080404A1 PE 20080404 A1 PE20080404 A1 PE 20080404A1 PE 2007000936 A PE2007000936 A PE 2007000936A PE 2007000936 A PE2007000936 A PE 2007000936A PE 20080404 A1 PE20080404 A1 PE 20080404A1
Authority
PE
Peru
Prior art keywords
benzyl
amino
cycloalkyl
alkyl
ester
Prior art date
Application number
PE2007000936A
Other languages
English (en)
Inventor
Hidetomo Imase
Yuki Iwaki
Toshio Kawanami
Takahiro Miyake
Muneto Mogi
Osamu Ohmori
Hongbo Qin
Ichiro Umemura
Ken Yamada
Kayo Yasoshima
Original Assignee
Novartis Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=38695303&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=PE20080404(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Novartis Ag filed Critical Novartis Ag
Publication of PE20080404A1 publication Critical patent/PE20080404A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4468—Non condensed piperidines, e.g. piperocaine having a nitrogen directly attached in position 4, e.g. clebopride, fentanyl
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/455—Nicotinic acids, e.g. niacin; Derivatives thereof, e.g. esters, amides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D211/36—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D211/56—Nitrogen atoms
    • C07D211/58—Nitrogen atoms attached in position 4
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Diabetes (AREA)
  • Cardiology (AREA)
  • Hematology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Obesity (AREA)
  • Epidemiology (AREA)
  • Urology & Nephrology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Hospice & Palliative Care (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)
  • Vascular Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Hydrogenated Pyridines (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

SE REFIERE A UN COMPUESTO DE FORMULA I DONDE R1 ES CICLOALQUILO, HETEROCICLICO, ARILO, ENTRE OTROS; R2 ES ALQUILO, CICLOALQUILO, ALCOXI, ENTRE OTROS; R3 ES ALQUILO, CICLOALQUILO, ENTRE OTROS; R4 Y R5 SON CADA UNO H, ALQUILO, ALQUENILO, ENTRE OTROS; R6 Y R7 SON CADA UNO H, ALQUILO, CIANO, ENTRE OTROS. SON COMPUESTOS PREFERIDOS: TERBUTIL ESTER DEL ACIDO 4-[(3,5-BIS-TRIFLUORO-METIL-BENCIL)-METOXI-CARBONIL-AMINO]-2-ETIL-PIPERIDIN-1-CARBOXILICO; TERBUTIL- ESTER DE ACIDO 4-[ACETIL-(3,5-BIS-TRIFLUORO-METIL-BENCIL)-AMINO]-2-ETIL-PIPERIDIN-1-CARBOXILICO; ENTRE OTROS. REFERIDA TAMBIEN A UNA COMPOSICION FARMACEUTICA Y UN PROCEDIMIENTO DE PREPARACION. LOS COMPUESTOS DESCRITOS SON INHIBIDORES DE LA PROTEINA DE TRANSFERENCIA DE COLESTIRIL-ESTER(CETP) UTILES EN EL TRATAMIENTO DE HIPERLIPIDEMIA, DISLIPIDEMIA, HIPERTRIGLICERIDEMIA, Y DEMAS RELACIONADAS
PE2007000936A 2006-07-20 2007-07-19 Derivados bencil-amino-piperidina como inhibidores de cetp PE20080404A1 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP06117541 2006-07-20
US88705807P 2007-01-29 2007-01-29

Publications (1)

Publication Number Publication Date
PE20080404A1 true PE20080404A1 (es) 2008-06-27

Family

ID=38695303

Family Applications (1)

Application Number Title Priority Date Filing Date
PE2007000936A PE20080404A1 (es) 2006-07-20 2007-07-19 Derivados bencil-amino-piperidina como inhibidores de cetp

Country Status (22)

Country Link
US (1) US20090286790A1 (es)
EP (1) EP2049517B1 (es)
JP (1) JP5042311B2 (es)
KR (1) KR101149274B1 (es)
AR (1) AR061926A1 (es)
AU (1) AU2007276433B2 (es)
CA (1) CA2657258A1 (es)
CL (1) CL2007002107A1 (es)
CO (1) CO6150155A2 (es)
CR (1) CR10478A (es)
EC (1) ECSP099078A (es)
GT (1) GT200900010A (es)
HR (1) HRP20140183T1 (es)
IL (1) IL195792A (es)
MA (1) MA30638B1 (es)
MX (1) MX2009000646A (es)
NO (1) NO342106B1 (es)
PE (1) PE20080404A1 (es)
PL (1) PL2049517T3 (es)
TN (1) TN2009000012A1 (es)
TW (1) TWI387593B (es)
WO (1) WO2008009435A1 (es)

Families Citing this family (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2181110A2 (en) * 2007-07-13 2010-05-05 ADDEX Pharma S.A. Novel heteroaromatic derivatives and their use as positive allosteric modulators of metabotropic glutamate receptors
EP2025674A1 (de) 2007-08-15 2009-02-18 sanofi-aventis Substituierte Tetrahydronaphthaline, Verfahren zu ihrer Herstellung und ihre Verwendung als Arzneimittel
ES2381518T3 (es) * 2007-11-05 2012-05-29 Novartis Ag Derivados del 4-bencilamino-1-carboxi acil-piperidina como inhibidores de CETP útiles para el tratamiento de enfermedades tales como hiperlipidemia o arteroesclerosis
CN101878199B (zh) * 2007-12-03 2013-09-18 诺瓦提斯公司 用于治疗例如高血脂或动脉硬化疾病的作为cetp抑制剂的1，2-二取代的-4-苄基氨基-吡咯烷衍生物
AU2008335788B2 (en) 2007-12-12 2012-11-29 Amgen Inc. Glycine transporter-1 inhibitors
EP2582709B1 (de) 2010-06-18 2018-01-24 Sanofi Azolopyridin-3-on-derivate als inhibitoren von lipasen und phospholipasen
RU2572606C2 (ru) 2010-07-09 2016-01-20 Дайити Санкио Компани, Лимитед Замещенное пиридиновое соединение
US8877815B2 (en) 2010-11-16 2014-11-04 Novartis Ag Substituted carbamoylcycloalkyl acetic acid derivatives as NEP
US8673974B2 (en) 2010-11-16 2014-03-18 Novartis Ag Substituted amino bisphenyl pentanoic acid derivatives as NEP inhibitors
KR20190025737A (ko) 2011-07-08 2019-03-11 노파르티스 아게 높은 트리글리세리드 대상체에서의 아테롬성동맥경화증의 치료 방법
WO2013103150A1 (ja) 2012-01-06 2013-07-11 第一三共株式会社 置換ピリジン化合物の酸付加塩
UY35144A (es) 2012-11-20 2014-06-30 Novartis Ag Miméticos lineales sintéticos de apelina para el tratamiento de insuficiencia cardiaca
JP6295277B2 (ja) 2013-02-14 2018-03-14 ノバルティス アーゲー Ｎｅｐ（中性エンドペプチダーゼ）阻害剤としての置換ビスフェニルブタン酸ホスホン酸誘導体
JP2014172851A (ja) * 2013-03-07 2014-09-22 Chiba Univ ピラゾール誘導体の製造方法およびイソオキサゾール誘導体の製造方法
AU2014293386B2 (en) 2013-07-25 2016-11-17 Novartis Ag Cyclic polypeptides for the treatment of heart failure
JP2016527249A (ja) 2013-07-25 2016-09-08 ノバルティス アーゲー 合成アペリンポリペプチドのバイオコンジュゲート
JP6402907B2 (ja) * 2014-09-24 2018-10-10 Jnc株式会社 ピペリジン誘導体、液晶組成物および液晶表示素子
BR112017014194A2 (pt) 2015-01-23 2018-01-09 Novartis Ag conjugados de ácido graxo de apelina sintéticos com meia-vida melhorada
UY38072A (es) 2018-02-07 2019-10-01 Novartis Ag Compuestos derivados de éster butanoico sustituido con bisfenilo como inhibidores de nep, composiciones y combinaciones de los mismos
US11066404B2 (en) 2018-10-11 2021-07-20 Incyte Corporation Dihydropyrido[2,3-d]pyrimidinone compounds as CDK2 inhibitors
US11384083B2 (en) 2019-02-15 2022-07-12 Incyte Corporation Substituted spiro[cyclopropane-1,5′-pyrrolo[2,3-d]pyrimidin]-6′(7′h)-ones as CDK2 inhibitors
TW202100520A (zh) 2019-03-05 2021-01-01 美商英塞特公司 作為cdk2 抑制劑之吡唑基嘧啶基胺化合物
WO2020205560A1 (en) 2019-03-29 2020-10-08 Incyte Corporation Sulfonylamide compounds as cdk2 inhibitors
US11447494B2 (en) 2019-05-01 2022-09-20 Incyte Corporation Tricyclic amine compounds as CDK2 inhibitors
WO2020223469A1 (en) 2019-05-01 2020-11-05 Incyte Corporation N-(1-(methylsulfonyl)piperidin-4-yl)-4,5-di hydro-1h-imidazo[4,5-h]quinazolin-8-amine derivatives and related compounds as cyclin-dependent kinase 2 (cdk2) inhibitors for treating cancer
AU2020328025A1 (en) 2019-08-14 2022-03-03 Incyte Corporation Imidazolyl pyrimidinylamine compounds as CDK2 inhibitors
CN110508018B (zh) * 2019-09-03 2022-02-25 中国石油大学(华东) 生产聚甲氧基二甲醚的装置及方法
CN119930611A (zh) 2019-10-11 2025-05-06 因赛特公司 作为cdk2抑制剂的双环胺
US11981671B2 (en) 2021-06-21 2024-05-14 Incyte Corporation Bicyclic pyrazolyl amines as CDK2 inhibitors
US11976073B2 (en) 2021-12-10 2024-05-07 Incyte Corporation Bicyclic amines as CDK2 inhibitors

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PT72878B (en) 1980-04-24 1983-03-29 Merck & Co Inc Process for preparing mannich-base hydroxamic acid pro-drugs for the improved delivery of non-steroidal anti-inflammatory agents
US4889861A (en) 1982-12-21 1989-12-26 Ciba-Geigy Corp. Substituted imidazo[1,5-a]pyridine derivatives and other substituted bicyclic derivatives and their use as aromatase inhibitors
US4617307A (en) 1984-06-20 1986-10-14 Ciba-Geigy Corporation Substituted imidazo[1,5-A]pyridine derivatives as aromatase inhibitors
RU2086544C1 (ru) 1991-06-13 1997-08-10 Хоффманн-Ля Рош АГ Бензолсульфонамидные производные пиримидина или их соли, фармацевтическая композиция для лечения заболеваний, связанных с активностью эндотелина
MY110227A (en) * 1991-08-12 1998-03-31 Ciba Geigy Ag 1-acylpiperindine compounds.
US5508272A (en) 1993-06-15 1996-04-16 Bristol-Myers Squibb Company Compounds containing a fused bicycle ring and processes therefor
MY119161A (en) 1994-04-18 2005-04-30 Novartis Ag Delta-amino-gamma-hydroxy-omega-aryl-alkanoic acid amides with enzyme especially renin inhibiting activities
TW313568B (es) 1994-12-20 1997-08-21 Hoffmann La Roche
US6140342A (en) * 1998-09-17 2000-10-31 Pfizer Inc. Oxy substituted 4-carboxyamino-2-methyl-1,2,3,4-tetrahydroquinolines
CA2345103C (en) 1998-09-25 2011-04-26 Monsanto Company (r)-chiral halogenated 1-substitutedamino-(n+1)-alkanols useful for inhibiting cholesteryl ester transfer protein activity
ES2377318T3 (es) 2002-09-06 2012-03-26 Cerulean Pharma Inc. Polímeros a base de ciclodextrina para el suministro de los agentes terapéuticos enlazados covalentemente a ellos
CA2554455A1 (en) 2004-01-30 2005-08-11 Japan Tobacco Inc. Anorectic
MY150958A (en) * 2005-06-16 2014-03-31 Astrazeneca Ab Compounds for the treatment of multi-drug resistant bacterial infections
CN101878199B (zh) * 2007-12-03 2013-09-18 诺瓦提斯公司 用于治疗例如高血脂或动脉硬化疾病的作为cetp抑制剂的1，2-二取代的-4-苄基氨基-吡咯烷衍生物

Also Published As

Publication number Publication date
US20090286790A1 (en) 2009-11-19
CO6150155A2 (es) 2010-04-20
AU2007276433A1 (en) 2008-01-24
IL195792A (en) 2013-07-31
JP2009543827A (ja) 2009-12-10
MX2009000646A (es) 2009-01-29
AU2007276433B2 (en) 2011-06-16
PL2049517T3 (pl) 2014-06-30
NO20090756L (no) 2009-04-14
KR101149274B1 (ko) 2012-05-29
JP5042311B2 (ja) 2012-10-03
MA30638B1 (fr) 2009-08-03
CL2007002107A1 (es) 2008-06-06
TN2009000012A1 (en) 2010-08-19
NO342106B1 (no) 2018-03-26
AR061926A1 (es) 2008-10-01
IL195792A0 (en) 2009-09-01
WO2008009435A1 (en) 2008-01-24
EP2049517A1 (en) 2009-04-22
KR20090031579A (ko) 2009-03-26
TW200813022A (en) 2008-03-16
TWI387593B (zh) 2013-03-01
ECSP099078A (es) 2009-02-27
GT200900010A (es) 2009-06-24
EP2049517B1 (en) 2013-11-27
HK1132262A1 (en) 2010-02-19
CR10478A (es) 2009-02-02
CA2657258A1 (en) 2008-01-24
HRP20140183T1 (hr) 2014-04-11

Similar Documents

Publication Publication Date Title
PE20080404A1 (es) Derivados bencil-amino-piperidina como inhibidores de cetp
PE20121640A1 (es) Derivados de pirazina como inhibidores de bace
PE20081845A1 (es) Nuevos derivados de aminopirimidina como inhibidores de plk1
PE20080538A1 (es) Derivado heterociclico fusionado y su uso
PE20040780A1 (es) Compuestos heterociclicos como antagonista de cgrp y procedimiento para su preparacion
PE20090982A1 (es) Derivados de piperidina como inhibidores de la proteina de transferencia de colesteril-ester (cetp)
PE20090276A1 (es) Compuestos derivados de imidazoquinolina como moduladores de tlr7
PE20090709A1 (es) Compuestos heterociclico de 5 miembros
PE20141075A1 (es) 4-aril-n-fenil-1,3,5-triazin-2-aminas que contienen un grupo sulfoximina
PE20130647A1 (es) Indoles
PE20071156A1 (es) COMPUESTOS DERIVADOS DE 4,5,6,7-TETRAHIDRO-1H-INDAZOL COMO POTENCIADORES DEL RECEPTOR DEL ACIDO a-AMINO-3-HIDROXI-5-METILISOXAZOL-4-PROPIONICO (AMPA)
PE20030062A1 (es) Derivados aralquilsulfonil-3-(pirrol-2-ilmetiliden)-2-indolinona como inhibidores de quinasas
PE20142185A1 (es) Pirrolidina-2-carboxamidas sustituidas
PE20081314A1 (es) COMPUESTOS TRICICLICOS FUSIONADOS NO ESTEROIDALES COMO MODULADORES DEL RECEPTOR GLUCOCORTICOIDE, AP-1 Y/O ACTIVIDAD NF-kB
PE20121500A1 (es) 2-amino-5,5-difluor-5,6-dihidro-4h-oxazinas como inhibidores de bace 1 y/o bace 2
PE20080951A1 (es) DERIVADOS DE 2-OXO-ETIL-AMINO-PROPIONAMIDA-PIRROLIDIN-2-IL-SUSTITUIDOS COMO INHIBIDORES DEL ENLACE DE LA PROTEINA Smac AL INHIBIDOR DE LA PROTEINA DE APOPTOSIS
PE20120062A1 (es) Derivados de 1-bencil-2-amino-tetralina como inhibidores del transportador de glicina glyt1
PE20120632A1 (es) Inhibidores de bace
PE20081238A1 (es) Piperidinas sustituidas como antagonistas de hdm2
PE20110854A1 (es) DERIVADOS DE 1-FENIL-1H-PIRAZOLO[3,4-c]PIRIDINA-4-CARBONILAMINA COMO ANTAGONISTAS DE LOS RECEPTORES CCR1
PE20121157A1 (es) Compuestos heterociclicos como inhibidores de proteasas serinas
PE20130382A1 (es) Derivados de n-(imidazopirimidin-7-il)-heteroarilamida y su uso como inhibidores de pde10a
PE20060361A1 (es) Compuestos heterociclicos como inhibidores de la cinesina mitotica
PE20110328A1 (es) Compuestos heterociclicos fusionados como moduladores del receptor de la orexina
PE20080925A1 (es) DERIVADOS DE PIRROLO[2,3-b]PIRIDINA COMO INHIBIDORES DE QUINASA, EN PARTICULAR INHIBIDORES IKK2 (O IKK BETA)

Legal Events

Date Code Title Description
FG Grant, registration
FD Application declared void or lapsed